Phase I trial of TAS-102 and concurrent radiation therapy for patients with locally recurrent, unresectable or metastatic, rectal cancer.

TPS3623Background: After primary therapy for rectal cancer (chemotherapy, surgery, and/or radiotherapy), 7-10% of patients will develop locally recurrent disease. Re-irradiation +/- resection of re...